Our results presented herein warrant further examination of the therapeutic potential of already FDA-approved small molecule inhibitors as well as monoclonal antibodies targeting ERBB2 that could be repurposed for use in high-risk or R/R MM. The gene discussed is ERBB2; the disease is Miyoshi myopathy.